
Precipio PRPO
$ 27.9
-2.11%
Annual report 2025
added 03-30-2026
Precipio Total Shareholders Equity 2011-2026 | PRPO
Annual Total Shareholders Equity Precipio
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 14.6 M | 12.1 M | 14.4 M | 16.3 M | 24.6 M | 14.1 M | 13.2 M | 6.12 M | 13 M | -6.46 M | -12.8 M | 6.55 M | 11.4 M | 20.3 M | 11 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 24.6 M | -12.8 M | 10.6 M |
Quarterly Total Shareholders Equity Precipio
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 13.7 M | 12.3 M | 11.7 M | 12.1 M | 11.9 M | 12.1 M | 12.8 M | 14.4 M | 13 M | 14.1 M | 14.2 M | 16.3 M | 18.3 M | 20.6 M | 22.3 M | 24.6 M | 25.9 M | 27.3 M | 14.5 M | 14.1 M | 14.1 M | 14.1 M | 14.1 M | 13.2 M | 13.2 M | 13.2 M | 13.2 M | 6.12 M | 6.12 M | 6.12 M | 6.12 M | 13 M | 13 M | 13 M | 13 M | -6.46 M | -6.46 M | -6.46 M | -19.4 M | -2.1 M | -12.8 M | -12.8 M | -12.8 M | 6.55 M | 6.55 M | 6.55 M | 6.55 M | 11.4 M | 11.4 M | 11.4 M | 11.4 M | 20.3 M | 20.3 M | 20.3 M | 20.3 M | 11 M | 11 M | 11 M | 11 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 27.3 M | -19.4 M | 10.4 M |
Total Shareholders Equity of other stocks in the Diagnostics research industry
| Issuer | Total Shareholders Equity | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Centogene N.V.
CNTG
|
27.5 M | - | -6.23 % | $ 30.6 M | ||
|
Agilent Technologies
A
|
5.39 B | $ 116.92 | 2.67 % | $ 35.5 B | ||
|
Aspira Women's Health
AWH
|
-6.93 M | - | -6.19 % | $ 10.5 M | ||
|
Biocept
BIOC
|
8.86 M | - | -13.05 % | $ 7.29 M | ||
|
BioNano Genomics
BNGO
|
44.4 M | $ 1.18 | 0.85 % | $ 6.43 M | ||
|
Chembio Diagnostics
CEMI
|
17.8 M | - | 0.22 % | $ 16.8 M | ||
|
Enzo Biochem
ENZ
|
56.1 M | - | -8.98 % | $ 14.8 K | ||
|
DermTech
DMTK
|
57.2 M | - | -11.32 % | $ 2.94 M | ||
|
CareDx, Inc
CDNA
|
303 M | $ 17.92 | 1.41 % | $ 955 M | ||
|
Exact Sciences Corporation
EXAS
|
2.4 B | - | - | $ 19.8 B | ||
|
Akumin
AKU
|
-48.2 M | - | -17.87 % | $ 25.9 M | ||
|
Burning Rock Biotech Limited
BNR
|
1.85 B | $ 16.24 | 0.93 % | $ 175 M | ||
|
Co-Diagnostics
CODX
|
20.6 M | $ 4.4 | 101.83 % | $ 5.85 M | ||
|
Heska Corporation
HSKA
|
422 M | - | - | $ 1.31 B | ||
|
HTG Molecular Diagnostics
HTGM
|
5.39 M | - | -20.0 % | $ 1.06 M | ||
|
Interpace Biosciences
IDXG
|
22.4 M | $ 1.98 | -0.63 % | $ 8.76 M | ||
|
Illumina
ILMN
|
2.37 B | $ 128.0 | 1.23 % | $ 20.4 B | ||
|
Accelerate Diagnostics
AXDX
|
-22.3 M | - | -61.36 % | $ 2.46 M | ||
|
Castle Biosciences
CSTL
|
456 M | $ 25.19 | 1.45 % | $ 700 M | ||
|
Global Cord Blood Corporation
CO
|
4.88 B | - | - | $ 399 M | ||
|
Genetic Technologies Limited
GENE
|
16.4 M | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
1.69 B | - | 0.12 % | $ 80.1 M | ||
|
Laboratory Corporation of America Holdings
LH
|
8.62 B | $ 274.72 | 2.06 % | $ 22.9 B | ||
|
Charles River Laboratories International
CRL
|
3.16 B | $ 175.07 | 3.26 % | $ 8.68 B | ||
|
Medpace Holdings
MEDP
|
459 M | $ 520.65 | 2.39 % | $ 15 B | ||
|
Danaher Corporation
DHR
|
52.5 B | $ 196.19 | 2.71 % | $ 140 B | ||
|
Motus GI Holdings
MOTS
|
2.69 M | - | -34.28 % | $ 263 K | ||
|
Myriad Genetics
MYGN
|
368 M | $ 4.77 | 0.63 % | $ 442 M | ||
|
Neogen Corporation
NEOG
|
2.07 B | $ 10.34 | 3.61 % | $ 2.24 B | ||
|
National Research Corporation
NRC
|
14 M | $ 17.26 | 1.29 % | $ 386 M | ||
|
Natera
NTRA
|
706 M | $ 210.83 | 0.75 % | $ 20.7 B | ||
|
Invitae Corporation
NVTA
|
102 M | - | - | $ 21.2 M | ||
|
Organovo Holdings
ONVO
|
10.5 M | - | -2.3 % | $ 19.4 M | ||
|
OpGen
OPGN
|
7.38 M | - | -16.95 % | $ 1.54 M | ||
|
Fulgent Genetics
FLGT
|
1.13 B | $ 15.83 | -0.5 % | $ 479 M | ||
|
Pacific Biosciences of California
PACB
|
5.35 M | $ 1.47 | 2.08 % | $ 441 M | ||
|
Guardant Health
GH
|
-99.3 M | $ 92.84 | -0.49 % | $ 11.6 B | ||
|
PerkinElmer
PKI
|
7.25 B | - | -0.91 % | $ 14.7 B | ||
|
QIAGEN N.V.
QGEN
|
3.78 B | - | - | $ 10.6 B | ||
|
Psychemedics Corporation
PMD
|
6.67 M | - | -1.84 % | $ 15.3 M | ||
|
Personalis
PSNL
|
203 M | $ 6.33 | 2.59 % | $ 375 M | ||
|
Anixa Biosciences
ANIX
|
15.2 M | $ 2.73 | 1.49 % | $ 88.6 K | ||
|
Biomerica
BMRA
|
4.1 M | $ 2.15 | -0.46 % | $ 4.94 M | ||
|
Quotient Limited
QTNT
|
-35.6 M | - | -11.32 % | $ 1.1 M | ||
|
ICON Public Limited Company
ICLR
|
9.52 B | $ 106.54 | -0.58 % | $ 8.79 B | ||
|
Check-Cap Ltd.
CHEK
|
-1.45 M | - | - | $ 9.42 M | ||
|
Celcuity
CELC
|
101 M | $ 116.94 | 1.19 % | $ 5.47 B |